FINANCIAL RESULTS
After being in “remedial mode” for the past two years, JSE-listed pharmaceuticals giant Adcock Ingram is eyeing growth and development after generating healthy amounts of cash and accumulating “significant” resources during the year ended June 30. The group, which is progressing the sale of its lossmaking India assets, now aims to pursue its nonregulated product portfolio expansion plans through partnerships and acquisitions.
This content is only available to subscribers.
Forgot your password? Click here
Don't have any login details?
Free Trial Access